Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Active not recruiting 3Terminated 2Completed 2Recruiting 1

Sponsor Class

NETWORK 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Dermatologic 2CNS 2

Conditions

Melanoma 12Carcinoma, Non-Small-Cell Lung 8Neoplasms 5Neoplasm Metastasis 5Pancreatic Neoplasms 4Colorectal Neoplasms 3Lung Neoplasms 2Leukemia, Myeloid, Acute 2Brain Neoplasms 2Uterine Cervical Neoplasms 1Thrombocytosis 1Squamous Cell Carcinoma of Head and Neck 1Skin Neoplasms 1Relapsed Metastatic KRAS-Mutated Non-Small Cell Lung Cancer 1Rectal Neoplasms 1Prostatic Neoplasms 1Primary Myelofibrosis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1Myelodysplastic Syndromes 1Multiple Myeloma 1Lymphoma, Non-Hodgkin 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Chronic-Phase 1Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 1Leukemia, Myeloid, Accelerated Phase 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia, Lymphocytic, Chronic, B-Cell 1Hodgkin Disease 1

Interventions

Temozolomide 28Radiosurgery 19Radiotherapy 17Bevacizumab 12Magnetic Resonance Spectroscopy 9Radiation 6Erlotinib Hydrochloride 6Carboplatin 6Topotecan 5Nivolumab 5Mental Status and Dementia Tests 5Irinotecan 5Capecitabine 5pembrolizumab 4dabrafenib 4Trastuzumab 4Sunitinib 4Pemetrexed 4Ipilimumab 4Filgrastim 4Cyclophosphamide 4Aminolevulinic Acid 42,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide 4cabozantinib 3Vorinostat 3TPI-287 3Specimen Handling 3Radiotherapy, Intensity-Modulated 3Methylphenidate 3Lomustine 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × Brain Neoplasms × trametinib × Clear all
NCT02974803 2021-08-20

Concurrent Dabrafenib + Trametinib With Sterotactic Radiation in BRAF Mutation-Positive Malignant Melanoma and Brain Metastases

Canadian Cancer Trials Group

Phase 2 Terminated
6 enrolled 3 charts
CNSDermatologic

Brain Neoplasms, Melanoma

NCT01978236 2018-08-17

Dabrafenib/Trametinib, BRAF or BRAF AND MEK Pre-op With BRAF and MEK Post-op, Phase IIB, Melanoma With Brain Mets,Biomarkers and Metabolites

GlaxoSmithKline

Phase 2 Terminated
6 enrolled 9 charts
CNSDermatologic

Brain Neoplasms, Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡